"Zonisamide"

Zonisamide: as dangerous as topiramate during pregnancy? Register online | Log in | My PrescrireISSUE CONTENTSTOPICSABOUT PRESCRIREOFFERSenglish.prescrire.org > Spotlight > 100 most recent > Zonisamide: as dangerous as topiramate during pregnancy?SpotlightEvery month, the subjects in Prescrire’s Spotlight.100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90Spotlight100 most recentArchivesZonisamide: as dangerous as topiramate during pregnancy? Adverse Effects  The EMA has concluded that a pregnancy test should be "considered" before initiating treatment with zonisamide. Its close pharmacological similarity to topiramate, which has established teratogenic effects, plus the few available data, indicate the need for caution in women who are, or could become, pregnant.Full article available

Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs * Text only * * Home * Journals the use of levetiracetam or zonisamide as first line treatments in focal epilepsy or levetiracetam for newly diagnosed generalised epilepsy at 12 months. {{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}} Anthony G Marson, Girvan Burnside, Richard Appleton, Dave Smith, John Paul Leach, Graeme Sills, Catrin Tudur-Smith, Catrin O Plumpton, Dyfrig A Hughes, Paula R

Associations of Topiramate and Zonisamide Use With Kidney Stones: A Retrospective Cohort Study. Driven by expanding indications, topiramate and zonisamide utilization has increased over time. This trend may be associated with greater occurrence of kidney stones given the effects of these medications on urine chemistries. We sought to examine the relationship between topiramate and zonisamide use and kidney stone risk. Retrospective cohort study. Individuals in Optum's de-identified Clinformatics® Data Mart Database (CDM) and Medicare enrollees with at least one prescription filled for topiramate or zonisamide between January 1, 2011 and September 30, 2019, and age- and sex-matched controls. New topiramate or zonisamide use. Symptomatic stone event defined as an emergency department visit

Baseline gut microbiome and metabolites are correlated with alcohol consumption in a zonisamide clinical trial of heavy drinking alcoholic civilians. Development and severity of alcohol use disorder (AUD) has been linked to variations in gut microbiota and their associated metabolites in both animal and human studies. However, the involvement of the gut microbiome in alcohol consumption of individuals with AUD undergoing treatment remains unclear. To address this, stool samples (n=48) were collected at screening (baseline) and trial completion from a single site of a multi-site double-blind, placebo-controlled trial of Zonisamide in individuals with AUD. Alcohol consumption, gamma-glutamyl transferase (GGT), and phosphatidylethanol (PEth)levels were measured both at baseline and endpoint

Role of zonisamide in advanced Parkinson's disease: a randomized placebo-controlled study. Zonisamide (ZNS) has shown some efficacy in motor symptoms of PD; however, more evidence is lacking, and its effects on nonmotor symptoms (NMSs) and quality of life (QoL) remain to be investigated. This randomized double-blinded placebo-controlled crossover study investigated the effect of ZNS on motor

The relationship between anti-seizures medications and metabolic acidosis in craniotomy operations: is topiramate or zonisamide the cause of metabolic acidosis? The most commonly prescribed anti-seizures medications (ASMs) for the treatment of epilepsy are currently topiramate, zonisamide, lacosamide, carbamazepine and levetiracetam. The objective of this study was to examine the correlation of the ASMs administered before intracranial surgery (Group-I, zonisamide or topiramate; Group-II, lacosamide; Group-III, carbamazepine; Group-IV, levetiracetam). Metabolic acidosis severity was defined based on base excess (BE) levels: mild (-3 to -5), moderate (-5 to -10), and severe (below - 10). The study investigated the correlation between ASMs and the severity of metabolic acidosis in preoperative

Results from a randomized controlled trial of zonisamide in the treatment of alcohol use disorder. There is preliminary evidence that the anticonvulsant medication Zonisamide (ZON) may be an effective, well-tolerated treatment for alcohol use disorder (AUD). However, further evaluation of its efficacy for treating patients with AUD is needed, and much remains unknown about ZON's therapeutic

Effect of zonisamide on sleep and rapid eye movement sleep behavioral disorders in patients with Parkinson's disease: A randomized control trial. Zonisamide is a medication developed in Japan that is effective for motor symptoms and wearing off in Parkinson's disease (PD). Zonisamide has properties that may improve sleep disorders. The aim of this study is to verify the safety and efficacy of zonisamide for sleep disorders and rapid eye movement (REM) sleep behavioral disorders (RBD) using a mobile two-channel electroencephalography /electrooculography recording system in patients with PD. The present study is a single-blind randomized placebo-controlled trial. The subjects in the treatment group took zonisamide (25 mg per day) before bedtime. The primary outcome was sleep efficiency

Zonisamide and COVID-19 vaccination and Steven Johnson syndrome Zonisamide and COVID-19 vaccination and SJS Cookie NoticeThis site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.OK skip to main content Toggle site navigation * Annual Meeting * Ask the Expert * Journals * Find An Allergist / Immunologist * Biblioteca de Condiciones * Video Library * School Tools * AboutToggle sub-navigation * About the AAAAI * About Allergists / Immunologists * AAAAI Diversity Equity and Inclusion Statement * Membership * Advocacy * News & Press * Service and Stewardship * Strategic Relationships * Organizational Support 1. Allergist Resources 2. Ask the Expert 3. Zonisamide

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy | Advice | NICE 1. Home 2. NICE Guidance 3. Conditions and diseases 4. Neurological conditions 5. Epilepsy Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy

Efficacy evaluation of a commercially available MCT enriched therapeutic diet on dogs with idiopathic epilepsy treated with zonisamide: a prospective, randomized, double-blinded, placebo-controlled, crossover dietary preliminary study. Idiopathic epilepsy (IE) is a common, chronic brain dysfunction in dogs. Recently, the effect of feeding a diet enriched with medium-chain triglycerides (MCTs ) on seizure frequency has been evaluated in several studies in dogs with IE. However, most dogs with IE in previous studies were treated with phenobarbital as the main antiseizure medication (ASM). In Japan, zonisamide (ZNS) is the most prescribed ASM for dogs with IE. The interaction between ZNS and various nutrients including MCTs and the potential effects on treatment efficacy resulting from combining

Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study. In patients with dementia with Lewy bodies (DLB), it is unknown whether adjunct zonisamide is as effective and safe as increasing levodopa dose when levodopa has inadequate efficacy on parkinsonism . To compare adjunct zonisamide 25 mg/day versus an increased levodopa dose (increased by 100 mg/day) in patients with DLB treated with levodopa ≤300 mg/day for parkinsonism. The DUEL study was a multicenter, randomized, controlled, open-label, parallel-group, interventional, non-inferiority trial. During the observation period, levodopa was administered at ≤300 mg/day for 4 weeks. Subsequently, patients

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient evidence of clinical effectiveness and cost-effectiveness. We aimed to assess the long-term clinical effectiveness and cost-effectiveness of levetiracetam and zonisamide compared with lamotrigine in people with newly diagnosed focal epilepsy. This randomised, open-label, controlled trial compared levetiracetam and zonisamide with lamotrigine as first-line treatment

Zonisamide Mylan - partial seizures 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 28 January 2016 EMA/170957/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Zonisamide Mylan International non-proprietary name: zonisamide Procedure No.: EMEA/H/C/004127/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Zonisamide Mylan Assessment report EMA/170957/2016 Page 2/22 Table of contents 1. Background information on the procedure .............................................. 4 1.1. Submission of the dossier

Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial. To evaluate the long-term efficacy and safety of zonisamide, an antiepileptic agent, in dementia with Lewy bodies (DLB). Phase three clinical trial with 12 week, randomized, placebo-controlled, double-blind , and subsequent 40 week, open-label, extension periods. A total of 109 centers in Japan between April 2015 and November 2017. Outpatients diagnosed with probable DLB. Outpatients were randomly assigned to receive placebo (P) or zonisamide 25 or 50 mg/day for 12 weeks. In the subsequent open-label 40 week period, all patients initially received zonisamide 25 mg/day for at least 2 weeks followed by optional

Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial. and objective: Tremor is a disabling symptom of PD that usually responds poorly to available standard pharmacological agents. This study aimed to assess the effect of Zonisamide 25 mg on tremor in tremor-dominant PD patients as compared to placebo. This was a randomized, placebo-controlled, double -blind study. Parkinson's disease patients were allocated either to the intervention group (standard treatment along with Zonisamide 25 mg add-on) or the placebo group (standard treatment along with placebo). Baseline Unified Parkinson's Disease Rating Scale (UPDRS) and Tremor Research Group Essential Tremor Rating Scale (TETRAS) scores, as well as accelerometric tremor analysis were done and follow-up

Comparative whole transcriptome analysis of Parkinson's disease focusing on the efficacy of zonisamide. Interindividual variations in responsiveness to zonisamide in patients with Parkinson's disease (PD) have been observed in clinical settings. To decipher the molecular mechanisms determining the efficacy of zonisamide, we conducted whole transcriptome sequencing analysis of patients with PD . We selected 23 super-responders (SRs) and 25 non-responders (NRs) to zonisamide from patients with PD who had participated in a previous clinical trial for the approval of zonisamide for the treatment of 'wearing-off'. Whole transcriptome analysis of peripheral blood was conducted on samples taken before and 12 weeks after zonisamide treatment. We performed differential gene expression analysis

Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".

Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials. Although previous phase II and III clinical trials conducted in Japan showed that zonisamide improved parkinsonism in patients with dementia with Lewy bodies (DLB), some differences in efficacy outcomes were observed between the trials. We aimed to further examine the efficacy and safety of zonisamide in DLB patients with parkinsonism in a post hoc analysis of pooled data from the previous phase II and III trials. Both trials featured a 4-week run-in period followed by a 12-week treatment period with a double-blind, placebo-controlled, parallel-group, randomized, multicenter trial design. In our pooled analysis, the primary

Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. Although phase 2 and 3 clinical trials in Japan showed that zonisamide improved wearing off in patients with Parkinson's disease (PD), no studies to date have evaluated whether zonisamide improves wearing off in patients with PD without exacerbating dyskinesia. Therefore, we examined this hypothesis in a post hoc analysis of pooled data from the previous phase 2 and 3 trials. Both trials evaluated zonisamide 25 mg and 50 mg versus placebo during a 12-week treatment period. In our analysis, primary efficacy variables were adjusted mean change in wearing off (evaluated as change in "off" time) and dyskinesia from baseline to 12 weeks. Dyskinesia